Daiichi Sankyo and Lilly continue talks with FDA re Prasugrel NDA

Daiichi Sankyo and Lilly are continuing to have discussions with the FDA regarding the review of the NDA for Prasugrel

FDA extends prasugrel review period

The FDA has extended the review period for the prasugrel for the treatment of patients with acute coronary syndromes. The drug, codeveloped by Daiichi Sankyo and Lilly was initially granted priority review. The new FDA action date is September 26, 2008.

Daiichi-Sankyos Angiotensin II 1 antagonist olmesartan reverses blood vessel damage

Olmesartan medoxomil has been found to be effective at reversing the narrowing of the arteries that occurs in patients with hypertension. Treatment improved structural abnormalities of resistance arteries.

Watson’s alpha adrenergic antagonist silodesin safe in QTc studies

Watsons alpha 1 antagonist silodosin, under development for BPH releated dysuria has been shown to be safe and to not exhibit QTc effects

Azor shows efficacy in difficult to treat patient groups

Data presented at ASH shows that Azor (amlodipine and olmesartan medoxomil) safely and effectively lowered blood pressure, especially in several key difficult to treat patient groups such as in those of African and Hispanic/Latino decent

Benicar effective at restoring normotension

45% of hypertension patients treated with Daiichi Sankyo’s Angiotensin II 1 antagonist Benicar (olmesartan) reach normotension

Forest and Daiichi Sankyo end Azor co promotion agreement

Forest has terminated it’s co-promotion agreement for Azor (amlodipine and olmesartan medoxomil) with Daiichi Sankyo. Forest has determined that its resources will be better utilized in providing additional support for Forest’s currently marketed products.